• Toggle Accessibility Statement
  • Home
  • Skip to Main Content
  • Sitemap
×
  • Home
  • HTA Governance
    • Universal Health Care Act
    • Administrative Order on HTA
    • Philippine HTA Process Guide
    • Philippine HTA Methods Guide
      • Methods Guide for Clinical Equipment and Devices
      • Guidance Document for the Use of Real-World Evidence
    • Philippine HTA Code of Conduct
  • About Us
    • Mission/Vision
    • Health Technology Assessment Council (HTAC)
    • Health Technology Assessment Division (HTAD)
    • Road to HTA Institutionalization
    • External Partners
  • Publications
    • Omnibus HTA Tracker
    • HTA Topic Priority Lists
      • HTA TOPIC PRIORITY LIST (Cycle 1)
      • HTA TOPIC PRIORITY LIST (Cycle 2)
    • Assessments
    • Evidence Briefs
    • Issuances
    • Events and Press Releases
    • Annual Reports
      • 2023 Annual Report
      • 2022 Annual Report
      • 2021 Annual Report
      • 2020 Annual Report
      • 2019 Annual Report
    • FAQs on HTA
  • Get Involved with Us
    • Topic Nomination
    • Call for Proposals
    • Appeals
    • Careers
    • Contact Us
  • AUXILIARY MENU
Menu
GOVPH
  • GOVPH
  • Home
  • HTA Governance
    • Universal Health Care Act
    • Administrative Order on HTA
    • Philippine HTA Process Guide
    • Philippine HTA Methods Guide
      • Methods Guide for Clinical Equipment and Devices
      • Guidance Document for the Use of Real-World Evidence
    • Philippine HTA Code of Conduct
  • About Us
    • Mission/Vision
    • Health Technology Assessment Council (HTAC)
    • Health Technology Assessment Division (HTAD)
    • Road to HTA Institutionalization
    • External Partners
  • Publications
    • Omnibus HTA Tracker
    • HTA Topic Priority Lists
      • HTA TOPIC PRIORITY LIST (Cycle 1)
      • HTA TOPIC PRIORITY LIST (Cycle 2)
    • Assessments
    • Evidence Briefs
    • Issuances
    • Events and Press Releases
    • Annual Reports
      • 2023 Annual Report
      • 2022 Annual Report
      • 2021 Annual Report
      • 2020 Annual Report
      • 2019 Annual Report
    • FAQs on HTA
  • Get Involved with Us
    • Topic Nomination
    • Call for Proposals
    • Appeals
    • Careers
    • Contact Us
    • Accessibility Statement
    • High Contrast
    • Skip to Content
    • Skip to Footer
    • Default Text Size
    • Reduce Text Size - -
    • Enlarge Text Size + +

DOST - Health Technology Assessment Official Logo
Republic of the Philippines
DOST - Health Technology Assessment

Philippine Standard Time:

Pazopanib as treatment for Renal Cell Carcinoma

Insulin lispro (Mix – P 814 3ml pre-filled pen (100 U/mL); Insulin Lispro 100 Units/mL, 10 ml vial)

Insulin glulisine (100 IU/mL, 10 mL vial and 3 mL pre-filled pen) for Type 1 and Type 2 Diabetes Mellitus

Insulin aspart (100 U/mL) for Type 1 and Type 2 Diabetes Mellitus

Dexamethasone for diabetic macular edema

Post navigation

Newer posts →